Allogeneic immune replacement as cancer immunotherapy

Expert Opin Biol Ther. 2003 Oct;3(7):1051-60. doi: 10.1517/14712598.3.7.1051.


The graft-versus-leukaemia (GVL) reaction that occurs after allogeneic haematopoietic cell transplantation (HCT) can cure patients with a variety of haematological malignancies. A heightened appreciation of the GVL effect has resulted in the development of reduced intensity transplant approaches, where antitumour effects occur predominantly as a consequence of the transplanted donor immune system. The recent success of these transplants in patients with acute and chronic leukaemias has led to trials investigating for graft-versus-tumour (GVT) effects in patients with treatment-refractory metastatic solid tumours. This review discusses evidence that immune replacement following allogeneic HCT is a potent form of cancer immunotherapy for patients with haematological and non-haematological malignancies.

Publication types

  • Review

MeSH terms

  • Animals
  • Graft vs Host Disease
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunotherapy / trends*
  • Leukemia / immunology
  • Leukemia / therapy
  • Neoplasms / therapy*
  • Transplantation, Homologous